Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma

Cell Death and Disease

Volumn 5, Issue 7, 2014, Pages

  Semba, K ^a,b   Namekata, K ^a   Kimura, A ^a   Harada, C ^a   Mitamura, Y ^b   Harada, T ^a,b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; EXCITATORY AMINO ACID TRANSPORTER 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTECTIVE AGENT; QUINOXALINE DERIVATIVE; SLC1A1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAM; IN VIVO STUDY; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MOUSE; NERVE DEGENERATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINA DEGENERATION; RETINA GANGLION CELL; VISION; ANIMAL; DRUG EFFECTS; FEMALE; GENETICS; GLAUCOMA; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOPHYSIOLOGY; RETINAL DEGENERATION;

ANIMALS; EXCITATORY AMINO ACID TRANSPORTER 3; FEMALE; GLAUCOMA; HUMANS; MALE; MICE; MICE, KNOCKOUT; PROTECTIVE AGENTS; QUINOXALINES; RECEPTORS, N-METHYL-D-ASPARTATE; RETINAL DEGENERATION; RETINAL GANGLION CELLS;

EID: 84905463074     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.306     Document Type: Article

References (47)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267
2. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S et al. The prevalence of primary open-angle glaucoma in Japanese: The Tajimi Study. Ophthalmology 2004; 111: 1641-1648
3. Harada T, Harada C, Nakamura K, Quah HA, Okumura A, Namekata K et al. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117: 1763-1770
4. Desai PV, Caprioli J. The treatment of normal-tension glaucoma. Prog Brain Res 2008; 173: 195-210
5. Namekata K, Kimura A, Kawamura K, Guo X, Harada C, Tanaka K et al. Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma. Cell Death Differ 2013; 20: 1250-1256
6. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105
7. Harada T, Harada C, Watanabe M, Inoue Y, Sakagawa T, Nakayama N et al. Functions of the two glutamate transporters GLAST and GLT-1 in the retina. Proc Natl Acad Sci USA 1998; 95: 4663-4666
8. Namekata K, Harada C, Guo X, Kikushima K, Kimura A, Fuse N et al. Interleukin-1 attenuates normal tension glaucoma-like retinal degeneration in EAAC1-deficient mice. Neurosci Lett 2009; 465: 160-164
9. Harada C, Namekata K, Guo X, Yoshida H, Mitamura Y, Matsumoto Y et al. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ 2010; 17: 1751-1759
10. Semba K, Namekata K, Guo X, Harada C, Harada T, Mitamura Y. Renin-angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis (in press)
11. Osborne NN. Pathogenesis of ganglion 'cell death' in glaucoma and neuroprotection: Focus on ganglion cell axonal mitochondria. Prog Brain Res 2008; 173: 339-352
12. Plafker SM. Oxidative stress and the ubiquitin proteolytic system in age-related macular degeneration. Adv Exp Med Biol 2010; 664: 447-456
13. Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 1940-1944
14. Akman A, Cetinkaya A, Akova YA, Ertan A. Comparison of additional intraocular pressurelowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye 2005; 19: 145-151
15. Metoki T, Ohguro H, Ohguro I, Mamiya K, Ito T, Nakazawa M. Study of effects of antiglaucoma eye drops on N-methyl-D-aspartate-induced retinal damage. Jpn J Ophthalmol 2005; 49: 453-461
16. Lee KY, Nakayama M, Aihara M, Chen YN, Araie M. Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells. Mol Vis 2010; 16: 246-251
17. Lee D, Kim KY, Noh YH, Chai S, Lindsey JD, Ellisman MH et al. Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One 2012; 7: e47098
18. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49: 4515-4522
19. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000; 41: 4169-4174
20. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120: 797-803
21. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16: 5986-5992
22. Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002; 19: 175-185
23. Fujita Y, Sato A, Yamashita T. Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation. Cell Death Dis 2013; 4: e763
24. Harada C, Guo X, Namekata K, Kimura A, Nakamura K, Tanaka K et al. Glia- and neuron-specific functions of TrkB signalling during retinal degeneration and regeneration. Nat Commun 2011; 2: 189
25. Peng M, Li Y, Luo Z, Liu C, Laties AM, Wen R. Alpha2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Müller cells in vivo. Invest Ophthalmol Vis Sci 1998; 39: 1721-1726
26. Katome T, Namekata K, Guo X, Semba K, Kittaka D, Kawamura K et al. Inhibition of ASK1-p38 pathway prevents neural cell death following optic nerve injury. Cell Death Differ 2013; 20: 270-280
27. Hasegawa S, Ohshima A, Hayakawa Y, Takagi M, Abe H. Multifocal electroretinograms in patients with branch retinal artery occlusion. Invest Ophthalmol Vis Sci 2013; 2: 298-304
28. Sutter EE, Bearse Jr MA. The optic nerve head component of the human ERG. Vision Res 1999; 39: 419-436
29. Aihara M, Lindsey JD, Weinreb RN. Twenty-four-hour pattern of mouse intraocular pressure. Exp Eye Res 2003; 77: 681-686
30. Harada T, Harada C, Nakayama N, Okuyama S, Yoshida K, Kohsaka S et al. Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. Neuron 2000; 26: 533-541
31. Harada T, Harada C, Kohsaka S, Wada E, Yoshida K, Ohno S et al. Microglia-Müller glia cell interactions control neurotrophic factor production during light-induced retinal degeneration. J Neurosci 2002; 22: 9228-9236
32. van Velthoven ME, Faber DJ, Verbraak FD, van Leeuwen TG, de Smet MD. Recent developments in optical coherence tomography for imaging the retina. Prog Retin Eye Res 2007; 26: 57-77
33. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151: 671-681
34. Zhang K, Zhang L, Weinerb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 2012; 11: 541-559
35. Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J. Dendritic function of tau mediates amyloid-b toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397
36. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010; 65: 178-190
37. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P et al. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res 2009; 28: 423-451
38. Knox DL, Eagle Jr RC, Green WR. Optic nerve hydropic axonal degeneration and blocked retrograde axoplasmic transport: histopathologic features in human high-pressure secondary glaucoma. Arch Ophthalmol 2007; 125: 347-353
39. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764-774
40. Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci USA 2009; 106: 13469-13474
41. Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC et al. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. J Biol Chem 2010; 285: 39392-39400
42. Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol 2007; 67: 884-894
43. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: 2849-2855
44. Vidal L, Díaz F, Villena A, Moreno M, Campos JG, Pérez de Vargas I. Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res Bull 2010; 82: 18-24
45. Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med 2010; 10: 267-278
46. Kolomeyer AM, Zarbin MA. Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Surv Ophthalmol 2014; 59: 134-165
47. Guo X, Nakamura K, Kohyama K, Harada C, Behanna HA, Watterson DM et al. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. Neurosci Res 2007; 59: 457-466.